Published in J Exp Med on February 03, 1997
microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity (2007) 6.72
In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J Exp Med (1997) 3.75
In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines. J Exp Med (1999) 3.69
A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med (2001) 3.36
Germinal centers without T cells. J Exp Med (2000) 2.25
T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J Exp Med (1998) 1.91
Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. J Exp Med (2000) 1.87
HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. Nat Immunol (2010) 1.70
Regulation of lymph node vascular growth by dendritic cells. J Exp Med (2006) 1.62
Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol (2008) 1.34
Dynamic changes during the immune response in T cell-antigen-presenting cell clusters isolated from lymph nodes. J Exp Med (2003) 1.08
CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche. Proc Natl Acad Sci U S A (2009) 1.04
In vivo maturation and migration of dendritic cells. Immunology (2001) 1.01
Impaired germinal center responses and suppression of local IgG production during intracellular bacterial infection. J Immunol (2010) 1.00
Loss of CD154 impairs the Th2 extrafollicular plasma cell response but not early T cell proliferation and interleukin-4 induction. Immunology (2004) 0.89
A novel block to mouse mammary tumor virus infection of lymphocytes in B10.BR mice. J Virol (2007) 0.88
Trypanosoma cruzi infection induces a massive extrafollicular and follicular splenic B-cell response which is a high source of non-parasite-specific antibodies. Immunology (2010) 0.86
B-cell memory and the persistence of antibody responses. Philos Trans R Soc Lond B Biol Sci (2000) 0.85
Role of dendritic cells in the immune response induced by mouse mammary tumor virus superantigen. J Virol (1999) 0.83
A highly sensitive in vitro infection assay to explore early stages of mouse mammary tumor virus infection. J Virol (1997) 0.81
Immune response to mouse mammary tumor virus in mice lacking the alpha/beta interferon or the gamma interferon receptor. J Virol (1998) 0.80
The role of neutralizing antibodies for mouse mammary tumor virus transmission and mammary cancer development. Proc Natl Acad Sci U S A (2002) 0.78
Low cost delivery of proteins bioencapsulated in plant cells to human non-immune or immune modulatory cells. Biomaterials (2015) 0.78
Interleukin-4 up-regulates mouse mammary tumor virus expression yet is not required for in vivo virus spread. J Virol (2001) 0.78
The evolution within us. Philos Trans R Soc Lond B Biol Sci (2015) 0.76
The dendritic cell system and its role in immunogenicity. Annu Rev Immunol (1991) 23.09
Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 14.94
B lymphocytes secrete antigen-presenting vesicles. J Exp Med (1996) 11.53
Germinal centers. Annu Rev Immunol (1994) 10.85
Intraclonal generation of antibody mutants in germinal centres. Nature (1991) 7.39
Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity (1994) 7.22
Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell (1990) 6.33
Programmed cell death and extrathymic reduction of Vbeta8+ CD4+ T cells in mice tolerant to Staphylococcus aureus enterotoxin B. Nature (1991) 5.56
Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature (1989) 5.48
Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol (1991) 5.38
In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations. J Exp Med (1991) 4.98
The T-cell repertoire is heavily influenced by tolerance to polymorphic self-antigens. Nature (1988) 4.43
Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature (1991) 4.04
Identification of marrow-derived and thymus-derived small lymphocytes in the lymphoid tissue and thoracic duct lymph of normal rats. J Exp Med (1972) 3.54
In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. II. A common clonal origin for periarteriolar lymphoid sheath-associated foci and germinal centers. J Exp Med (1992) 3.13
Antigen-driven selection of virgin and memory B cells. Immunol Rev (1986) 3.10
Antigen-induced B-cell death and elimination during germinal-centre immune responses. Nature (1995) 2.95
T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes. J Immunol (1987) 2.93
Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J Immunol (1995) 2.72
Clonal expansion precedes anergy and death of V beta 8+ peripheral T cells responding to staphylococcal enterotoxin B in vivo. Eur J Immunol (1991) 2.71
Soluble antigen can cause enhanced apoptosis of germinal-centre B cells. Nature (1995) 2.65
Antigen-induced exclusion from follicles and anergy are separate and complementary processes that influence peripheral B cell fate. Immunity (1995) 2.55
Successful T cell priming in B cell-deficient mice. J Exp Med (1995) 2.52
The phenotype and fate of the antibody-forming cells of the splenic foci. Eur J Immunol (1996) 2.42
Antigen-driven B cell differentiation in vivo. J Exp Med (1993) 2.35
Relationship of germinal centers in lymphoid tissue to immunologic memory. VI. Transfer of B cell memory with lymph node cells fractionated according to their receptors for peanut agglutinin. J Immunol (1983) 2.29
Memory B cells in T cell-dependent antibody responses colonize the splenic marginal zones. Eur J Immunol (1988) 2.26
Positive selection determines T cell receptor V beta 14 gene usage by CD8+ T cells. J Exp Med (1989) 2.22
Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation. J Exp Med (1996) 2.18
Comparative migration of B- and T-Lymphocytes in the rat spleen and lymph nodes. Cell Immunol (1976) 2.14
Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission. Cell (1993) 2.11
The evolution of B-cell clones. Curr Top Microbiol Immunol (1990) 1.97
Distinct short-lived and long-lived antibody-producing cell populations. Eur J Immunol (1986) 1.89
Superantigens of mouse mammary tumor virus. Annu Rev Immunol (1995) 1.86
Induction of long-lived germinal centers associated with persisting antigen after viral infection. J Exp Med (1996) 1.80
Two monoclonal rat antibodies with specificity for the beta-chain variable region V beta 6 of the murine T-cell receptor. Proc Natl Acad Sci U S A (1988) 1.75
Superantigen-reactive CD4+ T cells are required to stimulate B cells after infection with mouse mammary tumor virus. J Exp Med (1993) 1.67
Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature (1993) 1.60
B cells are essential for murine mammary tumor virus transmission, but not for presentation of endogenous superantigens. J Exp Med (1994) 1.56
Germinal centers and antibody production in bone marrow. Immunol Rev (1992) 1.55
Sequential antigen-specific growth of T cells in the T zones and follicles in response to pigeon cytochrome c. Eur J Immunol (1996) 1.49
An exogenous mouse mammary tumor virus with properties of Mls-1a (Mtv-7). J Exp Med (1992) 1.45
Newly produced virgin B cells migrate to secondary lymphoid organs but their capacity to enter follicles is restricted. Eur J Immunol (1987) 1.30
Retroviral infection of neonatal Peyer's patch lymphocytes: the mouse mammary tumor virus model. J Exp Med (1994) 1.28
Clonal deletion of self-reactive T cells in irradiation bone marrow chimeras and neonatally tolerant mice. Evidence for intercellular transfer of Mlsa. J Exp Med (1989) 1.26
Soluble antigen abrogates the appearance of anti-protein IgG1-forming cell precursors during primary immunization. Proc Natl Acad Sci U S A (1990) 1.20
Antibody-forming cell induction during an early phase of germinal centre development and its delay with ageing. Immunology (1989) 1.09
Staphylococcal enterotoxins can reactivate experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A (1993) 1.00
Stimulation with specific antigen can block superantigen-mediated deletion of T cells in vivo. Proc Natl Acad Sci U S A (1994) 1.00
Virgin B cell recruitment and the lifespan of memory clones during antibody responses to 2,4-dinitrophenyl-hemocyanin. Eur J Immunol (1986) 0.98
Structure and biological activity of the subgenomic Mtv-6 endogenous provirus. Virology (1995) 0.93
New infectious mammary tumor virus superantigen with V beta-specificity identical to staphylococcal enterotoxin B (SEB). Eur J Immunol (1994) 0.91
Direct physical interaction involving CD40 ligand on T cells and CD40 on B cells is required to propagate MMTV. Immunity (1995) 0.90
Only a small proportion of splenic B cells in adults are short-lived virgin cells. Eur J Immunol (1993) 0.85
CD28/CTLA4-B7 interaction is dispensable for T cell stimulation by mouse mammary tumor virus superantigen but not for B cell differentiation and virus dissemination. Eur J Immunol (1996) 0.84
The methylation pattern of endogenous mouse mammary tumor virus proviral genes is tissue specific and stably inherited. Virology (1984) 0.84
Transfer of endogenous retroviral superantigen from donor to recipient B cells following priming to induce peripheral T cell tolerance. Cell Immunol (1995) 0.80
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med (1999) 6.27
Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol (1991) 5.38
Mechanism of antigen-driven selection in germinal centres. Nature (1990) 5.26
Antibody in the induction and inhibition of lymphocyte cytotoxicity. Transplant Rev (1972) 4.79
Circulating immune complexes in inflammatory bowel disease. Clin Exp Immunol (1973) 4.32
T-cell receptor V beta use predicts reactivity and tolerance to Mlsa-encoded antigens. Nature (1988) 4.04
A molecular basis for MHC class II--associated autoimmunity. Science (1988) 3.75
A human serum immunoglobulin with specificity for certain homologous target cells, which induces target cell damage by normal human lymphocytes. Immunology (1969) 3.12
Antigen-driven selection of virgin and memory B cells. Immunol Rev (1986) 3.10
Effect of specific antibody to target cells on their specific and non-specific interactions with lymphocytes. Nature (1968) 2.96
Competition for receptors for immunoglobulin on cytotoxic lymphocytes. Clin Exp Immunol (1972) 2.77
The first external domain of the nonobese diabetic mouse class II I-A beta chain is unique. Proc Natl Acad Sci U S A (1987) 2.77
Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. Eur J Immunol (1991) 2.71
Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice. Science (1992) 2.60
IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity (1997) 2.54
Germinal centres in T-cell-dependent antibody responses. Immunol Today (1992) 2.47
Complement facilitates early prion pathogenesis. Nat Med (2001) 2.30
Memory B cells in T cell-dependent antibody responses colonize the splenic marginal zones. Eur J Immunol (1988) 2.26
Germinal centers without T cells. J Exp Med (2000) 2.25
Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation. J Exp Med (1996) 2.18
The changing preference of T and B cells for partners as T-dependent antibody responses develop. Immunol Rev (1997) 2.16
Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. J Exp Med (1999) 2.15
Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci U S A (1990) 2.13
Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission. Cell (1993) 2.11
Marginal zones: the major B cell compartment of rat spleens. Eur J Immunol (1981) 2.08
T cell recognition as the target for immune intervention in autoimmune disease. Cell (1989) 2.04
Cytotoxic lymphocytes from rats depleted of thymus processed cells. Nat New Biol (1971) 2.02
Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med (2000) 1.99
The role of immunoglobulins in lymphocyte-mediated cell damage, in vitro. II. The mechanism of target cell damage by lymphoid cells from immunized rats. Immunology (1970) 1.96
T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J Exp Med (1998) 1.91
Predominant expression of a T cell receptor V beta gene subfamily in autoimmune encephalomyelitis. J Exp Med (1988) 1.89
Distinct short-lived and long-lived antibody-producing cell populations. Eur J Immunol (1986) 1.89
Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. J Exp Med (2000) 1.87
Recombinant 25-kDa CD23 and interleukin 1 alpha promote the survival of germinal center B cells: evidence for bifurcation in the development of centrocytes rescued from apoptosis. Eur J Immunol (1991) 1.82
Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med (1996) 1.80
Alpha-1-microglobulin: an indicator protein for renal tubular function. J Clin Pathol (1983) 1.80
Human major histocompatibility complex class II invariant chain is expressed on the cell surface. J Biol Chem (1990) 1.77
CD23: a multi-functional receptor/lymphokine? Immunol Today (1989) 1.76
Light chain isotype-associated suppression of normal plasma cell numbers in patients with multiple myeloma: Medical Research Council's Working Party for Leukaemia in Adults and the Oxford Lymphoma Group. Int J Cancer (1979) 1.75
Two monoclonal rat antibodies with specificity for the beta-chain variable region V beta 6 of the murine T-cell receptor. Proc Natl Acad Sci U S A (1988) 1.75
Identical V beta T-cell receptor genes used in alloreactive cytotoxic and antigen plus I-A specific helper T cells. Nature (1985) 1.74
Migrant mu+ delta+ and static mu+ delta- B lymphocyte subsets. Eur J Immunol (1982) 1.71
Superantigen-reactive CD4+ T cells are required to stimulate B cells after infection with mouse mammary tumor virus. J Exp Med (1993) 1.67
The V-region disease hypothesis: evidence from autoimmune encephalomyelitis. Immunol Today (1989) 1.66
Failure of certain cytotoxic lymphocytes to respond mitotically to phytohaemagglutinin. Nature (1970) 1.62
CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur J Immunol (1999) 1.62
A subset of CD4+ memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex. J Exp Med (1995) 1.60
Cytotoxic T cell clone-specific monoclonal antibodies used to select clonotypic antigen-specific cytotoxic T cells. Eur J Immunol (1985) 1.52
Immunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukaemia. Br Med J (1973) 1.50
CD4+CD3- cells induce Peyer's patch development: role of alpha4beta1 integrin activation by CXCR5. Immunity (2002) 1.49
Syk tyrosine kinase is required for the positive selection of immature B cells into the recirculating B cell pool. J Exp Med (1997) 1.46
The effect of peripheral lymphocytes from patients with inflammatory joint disease on human target cells in vitro. Clin Exp Immunol (1968) 1.46
An exogenous mouse mammary tumor virus with properties of Mls-1a (Mtv-7). J Exp Med (1992) 1.45
The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival. Q J Med (1991) 1.45
Dendritic cells associated with plasmablast survival. Eur J Immunol (1999) 1.44
Lymphocyte sensitivity to skeletal muscle in patients with polymyositis and other disorders. Clin Exp Immunol (1973) 1.41
Inhibitory effect of rheumatoid sera on cell damage by lymphocytes. Ann Rheum Dis (1972) 1.40
Immunosuppression in the treatment of inflammatory bowel disease. I. Changes in lymphoid sub-populations in the blood and rectal mucosa following cessation of treatment with azathioprine. Clin Exp Immunol (1974) 1.39
T-independent type 2 antigens induce B cell proliferation in multiple splenic sites, but exponential growth is confined to extrafollicular foci. Eur J Immunol (1999) 1.39
Changing responsiveness to chemokines allows medullary plasmablasts to leave lymph nodes. Eur J Immunol (2001) 1.38
Cells of the marginal zone of the spleen are lymphocytes derived from recirculating precursors. Eur J Immunol (1981) 1.36
Effector activating determinants on IgG. II. Differentiation of the combining sites for C1q from those for cytotoxic K cells and neutrophils by plasmin digestion of rabbits IgG. Immunology (1974) 1.36
The IgG subclass responses of human lymphocytes to B-cell activators. Immunology (1983) 1.35
Selective abrogation of major histocompatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene. J Exp Med (2001) 1.32
A polymorphic microsatellite in the tumor necrosis factor alpha promoter identifies an allele unique to the NZW mouse strain. J Exp Med (1990) 1.31
Differences in the recruitment of virgin B cells into antibody responses to thymus-dependent and thymus-independent type-2 antigens. Eur J Immunol (1986) 1.31
A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol (1998) 1.30
Newly produced virgin B cells migrate to secondary lymphoid organs but their capacity to enter follicles is restricted. Eur J Immunol (1987) 1.30
Peripheral T cell activation and deletion induced by transfer of lymphocyte subsets expressing endogenous or exogenous mouse mammary tumor virus. J Exp Med (1993) 1.29
Effector activating determinants on IgG. I. The distribution and factors influencing the display of complement, neutrophil and cytotoxic B-cell determinants on human IgG sub-classes. Immunology (1973) 1.29
Mouse mammary tumor virus: immunological interplays between virus and host. Adv Immunol (1997) 1.29
Retroviral infection of neonatal Peyer's patch lymphocytes: the mouse mammary tumor virus model. J Exp Med (1994) 1.28
Relation of intra-splenic migration of marginal zone B cells to antigen localization on follicular dendritic cells. Immunology (1984) 1.28
Evidence for correlation between the antigenic specificity and charge of human IgG. A study of antibody-inducing lymphocyte mediated cell damage. Immunology (1972) 1.25
Is rapid proliferation in B centroblasts linked to somatic mutation in memory B cell clones? Immunol Lett (1988) 1.24
Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. Eur J Immunol (2001) 1.21
Quantitative analysis of molecules which distinguish functional compartments within germinal centers. Eur J Immunol (1993) 1.20
Factors relating to circulating immune complexes in rheumatoid arthirits. Ann Rheum Dis (1976) 1.20
Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol (2001) 1.19
Characterization of cloned cytotoxic lymphocytes with NK-like activity. J Immunol (1983) 1.18
Lymphocyte-dependent cytotoxic antibody activity against human transplantation antigens. Transplantation (1973) 1.17
Results of the MRC myelomatosis trials for patients entered since 1980. Hematol Oncol (1988) 1.15
Co-stimulation and selection for T-cell help for germinal centres: the role of CD28 and OX40. Immunol Today (2000) 1.15
The distribution of antibody and antibody-producing cells after immunization with xenogeneic cells. Immunology (1972) 1.15
The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer (1985) 1.15
Impaired IgG2 anti-pneumococcal antibody responses in patients with recurrent infection and normal IgG2 levels but no IgA. Clin Exp Immunol (1986) 1.14
Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bc1-2 induction. Eur J Immunol (1993) 1.11
Selective depression of thymus-independent anti-DNP antibody responses induced by adult but not neonatal splenectomy. Clin Exp Immunol (1985) 1.10
Analysis of treatment in childhood leukaemia. II. Timing and the toxicity of combined 6-mercaptopurine and methotrexate maintenance therapy. Br J Haematol (1976) 1.10
Marginal zone B cells express CR1 and CR2 receptors. Eur J Immunol (1984) 1.10
Experimental myositis in rats. I. Histological and creatine phosphokinase changes, and passive transfer to normal syngeneic rats. Clin Exp Immunol (1974) 1.10
Reverse transcriptase-dependent and -independent phases of infection with mouse mammary tumor virus: implications for superantigen function. J Exp Med (1994) 1.09
Germinal center formation in mice lacking alpha beta T cells. Eur J Immunol (1996) 1.08
Cytotoxicity against human leukaemic cells. I. Demonstration of antibody-dependent lymphocyte killing of human allogeneic myeloblasts. Clin Exp Immunol (1973) 1.08